How long is IGF-1 LR3?

83 residues — more than twice the 40-amino-acid threshold that separates peptide from protein in regulatory frameworks.

Why does that matter practically?

It determines production route, impurity profile, and whether folding can go wrong independently of sequence.

Has a regulator classified it?

No. It holds no marketing authorisation anywhere. The point is what would apply, and what its documentation should therefore look like.

IGF-1 LR3

Eighty-Three Residues, and What That Changes

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Regulatory frameworks treat an amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug, and anything longer as a protein regulated as a biologic. IGF-1 LR3 is 83 residues, placing it firmly on the protein side.

Key facts

Threshold: 40 amino acids
IGF-1 LR3: 83 residues
Classification implied: Protein — biologic territory
For contrast, semaglutide: 31 residues — a drug
Production: Recombinant, not synthetic
Consequence: Different impurity and folding concerns

Why the line falls where it does

Below roughly forty residues a molecule can generally be synthesised chemically and characterised completely — every atom accounted for. Above it, synthesis becomes progressively impractical as coupling inefficiency compounds, and folding begins to determine function in ways analysis cannot fully capture. The threshold marks where complete characterisation stops being achievable.

Where this compound falls

Eighty-three residues, more than twice the threshold, with three disulfide bonds and a folded tertiary structure. It is produced by recombinant expression rather than solid-phase synthesis, which is not a coincidence — it is what a molecule of that size and complexity requires.

Research material referenced

IGF-1 LR3 1mg — third-party HPLC tested

View — £37.99

What that changes about the impurities

Everything. A synthetic peptide accumulates deletion sequences from incomplete couplings, detectable by mass. A recombinant protein has none of those, because ribosomal synthesis does not fail that way — instead it carries host cell proteins, host DNA and, from bacterial systems, endotoxin, none of which appears in a protein purity figure.

And what it changes about correctness

For a synthetic peptide, the right sequence is essentially the right molecule. For a folded protein with three disulfide bonds, the right sequence can still be the wrong molecule if the cysteines paired incorrectly — and a misfolded isomer has identical mass. Sequence correctness and molecular correctness separate at this size, and only above the threshold does that separation matter.

Why the classification is hypothetical here

IGF-1 LR3 holds no marketing authorisation anywhere, so no regulator has classified it. The point is what would apply if one did — and it explains why the compound's documentation should look like a recombinant protein's rather than a peptide's, which is the practical consequence regardless of regulatory status.

The contrast within this catalogue

Semaglutide at 31 residues, tirzepatide and retatrutide at 39 — all synthesisable, all fully characterisable, all handled as drugs. IGF-1 LR3 at 83 sits in a different technical world, and the difference shows up in how it is made, what can go wrong, and what a certificate needs to say. WADA class S2 applies to it regardless, at all times.

Quick reference

	≤40 residues	IGF-1 LR3, 83 residues
Typical production	Chemical synthesis	Recombinant expression
Characteristic impurity	Deletion sequences	Host protein, DNA, endotoxin
Folding a concern?	Rarely	Yes — three disulfides
Detectable by mass?	Impurities generally yes	Misfolds no

Extended research context

The IGF-1 LR3 deep dive

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications - arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension - exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete - at 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct - and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency - Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has essentially no primary literature under its own name - searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics precisely so that structural modification creates no exemption.

Research applications

▸Cell culture supplementation where secreted IGFBPs confound dosing
▸IGF binding protein interaction and affinity studies
▸Recombinant protein expression and purification methodology
▸Disulfide folding and oxidative refolding research
▸Comparative work on engineered versus native growth factors
▸Anti-doping analytical method development

Handling checklist

✓Expect no PubChem record - proteins are indexed in UniProt (native IGF-1 is P05019)
✓Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
✓Understand that mass spectrometry cannot detect a misfolded disulfide isomer
✓Treat loss of fold as the principal failure mode - it leaves mass unchanged
✓Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
✓Use low-binding consumables; adsorption is significant at microgram quantities
✓Aliquot before freezing - freeze-thaw is worse for a folded protein than a short peptide

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading mecasermin's approval as covering IGF-1 LR3

Fix: Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

✗ Expecting a synthetic-peptide certificate for a recombinant protein

Fix: There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

✗ Treating a clean mass spectrum as proof the protein is intact

Fix: A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

✗ Assuming absence from PubChem is a red flag

Fix: It is expected for a protein of this size - PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is genuinely odd.

✗ Reading the cell-culture rationale as transferable

Fix: Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How long is IGF-1 LR3?: 83 residues — more than twice the 40-amino-acid threshold that separates peptide from protein in regulatory frameworks.
Why does that matter practically?: It determines production route, impurity profile, and whether folding can go wrong independently of sequence.
Has a regulator classified it?: No. It holds no marketing authorisation anywhere. The point is what would apply, and what its documentation should therefore look like.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum